Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.35 |
| ▸ | CDK9 | P50750 | 9/20 | 0.35 |
| ▸ | TNF | P01375 | 2/20 | 0.35 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
| ▸ | EIF4EBP1 | Q13541 | 5/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16756255 | 0.93 | TSHR (0.36) | TSHRCCNT1CDK9TNFGPR6 | |
| SCHEMBL16756405 | 0.90 | GPR6 (0.36) | TSHRCCNT1CDK9GPR6EIF4EBP1 | |
| SCHEMBL16756412 | 0.85 | TNF (0.39) | CCNT1CDK9TNF | |
| SCHEMBL16756334 | 0.83 | CDK9 (0.36) | TSHRCCNT1CDK9GPR6 | |
| SCHEMBL16756364 | 0.81 | TNF (0.38) | TSHRTNFGPR6EIF4EBP1PTGER1 | |
| SCHEMBL16756450 | 0.81 | TNF (0.38) | TSHRTNFGPR6EIF4EBP1PTGER1 | |
| SCHEMBL16756509 | 0.74 | PPARD (0.36) | CDK9TNF | |
| SCHEMBL16756325 | 0.73 | TNF (0.41) | TNF | |
| SCHEMBL16756559 | 0.72 | TNF (0.41) | TNF | |
| SCHEMBL16756526 | 0.72 | TNF (0.41) | TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2858983-B1 | TNF-ALPHA MODULATING BENZIMIDAZOLES | UCB BIOPHARMA SPRL (BE) | 2018-04-18 | — | — | EP | disclosed |
| US-9550737-B2 | TNF -α modulating benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2017-01-24 | — | — | US | disclosed |
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | TNF, TNFRSF1A, NFKBIA | TSHR 1696/4885CCNT1 4233/4885CDK9 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.